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Abstract
Background:  In case of contraindications or intolerance during treatment with oral
bisphosphonates (OB), administration of pamidronate intravenously is a widely used alternative.
In this study we compared the effect on change in bone mineral density (BMD) of the spine and hip
during long term treatment with pamidronate iv in comparison to OB.
Methods:  We studied 61 patients receiving treatment for at least two years. In case of
contraindications or intolerance (within 3 months) of an OB, pamidronate iv was started. BMD was
measured on a Hologic 4500 and a Lunar DPX-IQ at the spine (L1-L4) and total hip.
Results: Thirty-one patients were enrolled in the OB group and 30 in the intravenous pamidronate
group. Mean follow-up duration (SD) was 4.3 (1.3) years. We observed a significant increase (p <
0.001) in spinal BMD, both in the OB group (8.3%) as well as in the pamidronate iv group (6.1%),
but no significant difference in BMD change between the OB and pamidronate iv groups. At the
hips, we observed a tendency to increased BMD in both groups, 1.1% in the OB and 1.4% in the
pamidronate iv group.
Conclusion:  We conclude that intravenous pamidronate is a good alternative for oral
bisphosphonates in the treatment of osteoporosis in patients with contraindications or intolerance
during treatment with oral bisphosphonates.
Background
In a previous one year prospective study we showed evi-
dence of a similar effectiveness of oral bisphosphonates
compared to pamidronate iv. [1] Patients were treated
with alendronate 10 mg orally once daily or pamidronate
60 mg intravenously every three months. In both groups
the BMD of the lumbar spine as well as the total hip
increased equally after one year of treatment. It is uncer-
tain however, whether the effect remains comparable after
a longer follow up period.
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Treatment with anti-osteoporotic drugs, such as bisphos-
phonates, has shown to effectively increase bone mineral
density (BMD) and reduce vertebral fracture risk by as
much as 40–50% [2,3] Fractures are the most important
clinical manifestation of osteoporosis and can cause sub-
stantial morbidity [4] and mortality [5]. Oral bisphospho-
nates however, may cause upper gastro intestinal side
effects such as dyspepsia and abdominal pain and are con-
traindicated in case of comorbidity of the upper gastroin-
testinal tract. [6,7]
In the current study, we observed the change in BMD of
lumbar spine and total hip after 2–5 years of treatment
with either pamidronate intravenously or oral bisphos-
phonates.
Methods
We performed a retrospective study at the osteoporosis
outpatient clinic of the Slotervaart Hospital (Amsterdam,
the Netherlands). After screening for osteoporosis, treat-
ment with anti-osteoporotic drugs was started, based on:
1) a T score of ≤ -2.5 at the spine and/or hip, 2) one or
more vertebral fractures (height loss more than 20%) or
3) a daily dose of prednisone of 7.5 mg or more during at
least three months, and a T-score < -1 at the spine or hips,
after which every one to two years patients returned to the
clinic for a follow up visit.
During the follow up visits, 61 consecutive patients
treated for at least two years with either an oral bisphos-
phonate (alendronate 70 mg weekly or risedronate 35 mg
weekly) or intravenous pamidronate (60 mg 3 monthly,
dissolved in 250 ml 0.9% saline) were enrolled. At that
time it was not unusual to retrospectively and anony-
mously collect data based on treatment effects of anti-
osteoporotic drugs in daily practice, without approval
from the ethics board. (all data were collected before
approval became mandatory).
The indications for intravenous pamidronate were con-
traindications for oral bisphosphonates or intolerance for
oral bisphosphonate therapy within three months from
the start of treatment. Patients with previous treatment for
longer than 3 months with anti-osteoporotic drugs were
not included.
Demographic data and data on risk factors for osteoporo-
sis at baseline and after a period of 2–5 years were col-
lected. The data collected at baseline included: type of
bisphosphonate (oral or pamidronate) and reason for
intravenous administration, age, body mass index (BMI),
menopausal status, history of clinical fractures (wrist,
ankle or hip), family (first degree) history of fractures, die-
tary intake of calcium, supplementation of calcium and/
or vitamin D, history of prednisone use and laboratory
testing including erythrocyte sedimentation rate, thyroid
stimulating hormone, free T4, creatinine, urea, alkaline
phosphatase, calcium and 25(OH) vitamin D.
BMD was measured with dual X-ray absorptiometry
(DXA) at the start of treatment and after 2–5 years in the
lumbar spine (L1-L4) and the total hip. The majority of
the measurements were performed on a Hologic 4500
(Waltham, Mass., USA) and some on a Lunar DPX-IQ
(Lunar). Repeated measurements in all patients were
done on the same machine.
Statistical analyses
To compare mean change in BMD between the groups
and within the groups we used the independent t-test and
paired student's t-test, respectively. The distribution of risk
factors and demographic data were compared between
groups using student's t-test for continuous variables and
using Pearson's chi-square test for dichotomous variables.
Results
The baseline characteristics of patients treated with
pamidronate iv or oral bisphosphonates are shown in
table 1. The mean duration of treatment was more than 4
years and comparable in both groups. There were no sig-
nificant differences between the groups in age, gender, age
at menopause, BMI, history of clinical vertebral or non-
vertebral fractures, family history of fractures, calcium
intake, use of prednisone or serum calcium, albumin or
25(OH) vitamin D level. Laboratory testing showed no
abnormalities in thyroid or kidney function. The BMD
and T scores of spine and hip at baseline were similar as
well.
Twenty-one patients (34%) used calcium supplementa-
tion because of an insufficient dietary calcium intake
(<1000 mg daily), twelve in the oral bisphosphonates
group and nine in the pamidronate iv group. A serum 25
(OH) vitamin D level below 30 nmol/l at baseline was an
indication to start supplementation with cholecalciferol.
Five patients treated with oral bisphosphonates were
given supplementation with vitamin D, as well as six in
the pamidronate iv group. In the oral bisphosphonates
group 17 patients were treated with alendronate 70 mg
weekly and 14 with risedronate 35 mg weekly.
During the outpatient clinic visits patients were asked
about their adherence to therapy. All patients confirmed
that they had taken their pills regularly, one patient
missed one infusion pamidronate due to a self-limiting
respiratory tract infection. Since it was a retrospective
study, and only patients who had tolerated their treat-
ment during at least two years were included, there are
hardly any data on side effects available.BMC Musculoskeletal Disorders 2009, 10:86 http://www.biomedcentral.com/1471-2474/10/86
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In the oral bisphosphonates group 21 out of 31 had a T
score of ≤ -2.5 at either spine or hip, 6 were using a high
dose of prednisone and 7 had a vertebral fracture. (three
patients had both a low T score and were using a high dose
of prednisone) In the pamidronte iv group 16 of the 30
had a T score of ≤ -2.5 at either spine or hip, 5 were using
a high dose of prednisone and 9 had a vertebral fracture.
The T scores by site or fracture history parameters that
resulted in study inclusion were the same in both groups.
The indication for treatment with pamidronate iv was
intolerance of oral bisphosphonates (22), gastrointestinal
complaints prior to treatment with oral bisphosphonates
(4) and a contraindication for oral treatment (4).
During the follow up period, three patients in the oral
bisphosphonates group and two in the pamidronate
group had a new non-vertebral osteoporotic fracture (two
ankle fractures and a hip fracture, and two hip fractures,
respectively). There were no new clinical vertebral frac-
tures.
Change in BMD
There was a small tendency to a larger increase of BMD in
patients using alendronate, eg in the spine the BMD
increased (SD) with 9 (8.7)% versus 7.5 (12)% in patients
using risedronate. However, these differences were not
significant, therefore further analyses has been performed
on all patients using oral bisphosphonates.
The BMD (SD) of the lumbar vertebral spine increased
with 0.058 (0.09) g/cm2 (+8.3% p < 0.001 vs baseline) in
the oral and 0.048 (0.05) g/cm2 (+6.1% p < 0.001 vs base-
line) in the pamidronate iv group. The BMD (SD) of the
hip increased non significantly in the oral group with
0.008 (0.046) g/cm2 (+1.1% p = 0.358) and 0.010 g/cm2
(0.046) (+1.4% p = 0.242) in the pamidronate iv group.
(table 2) There was no statistical difference between the
two groups in the effect on BMD in spine (p = 0.351) or
hip (p = 0.724).
Discussion
Oral bisphosphonates have shown to effectively prevent
bone loss and fractures. However, occasionally they can
cause gastrointestinal complaints. Furthermore, therapy
with oral bisphosphonates includes stringent require-
ments for fasting and posture during administration,
causing inconvenience for some patients. [8] The combi-
nation of possible gastrointestinal side effects and a com-
plex dosing regime can cause a decreased adherence,
which has been recognized as a problem in the treatment
of all chronic diseases.[9] Besides that, oral bisphospho-
nates are known for their poor bioavailability, which is
reported to be as low as 0.9–1.8% for alendronate and
risedronate.[10]
In case of gastrointestinal complaints, and in patients
with contraindications for oral bisphosphonates as a con-
sequence of abnormalities in the upper gastrointestinal
tract, particularly the oesophagus, intravenous adminis-
Table 1: Baseline characteristics of patients treated with pamidronate iv or oral bisphosphonates
Variables Oral Bisphosphonates n = 31 Pamidronate n = 30 p value
Duration of treatment (years) mean (range) 4.2 (4.9) 4.3 (4.8) 0.914
Age (years) mean (SD) 62 (13.9) 67 (9.6) 0.132
Gender (female) n (%) 24 (77) 24 (80) 0.527
Age at menopause (years) mean (SD) 48 (4.6) 46 (5.3) 0.178
BMI (kg/m2) mean (SD) 24 (4.7) 25 (4.5) 0.636
Number of patients with at least 1 clinical fracture n (%) 9 (29) 5 (17) 0.251
Familial fractures n (%) 12 (36) 11 (37) 0.516
Dietary calcium intake (mg/day) mean (SD) 925 (366) 838 (241) 0.293
Calcium supplementation daily dose (mg) n (%) 12 9 0.678
mean (SD) 541 (144) 610 (334) 0.531
Treatment with prednisone daily dose (mg) n (%) 6 (18) 5 (17) 0.835
mean (SD) 10 (4.2) 11.5 (6) 0.638
T score spine mean (SD) -2.39 (1.55) -2.58 (0.89) 0.562
T score hip mean (SD) -1.85 (1.13) -1.79 (1.03) 0.816
Serum 25(OH) D levels (nmol/l) mean (SD) 70 (31) 62 (29) 0.313
Serum calcium levels (mmol/l) mean (SD) 2.38 (0.1) 2.39 (0.1) 0.678
Serum albumin levels (g/l) mean (SD) 41 (9) 39 (4) 0.356
At baseline there are no significant differences between the oral bisphosphonates group and the pamidronate iv groupBMC Musculoskeletal Disorders 2009, 10:86 http://www.biomedcentral.com/1471-2474/10/86
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tration might be an attractive alternative. Furthermore, the
administration is less complex for the patients and it pro-
vides certainty to the physician that patients receive their
treatment. Also, bioavailability of intravenous adminis-
trated bisphosphonates is much better.
We realize that our study has limitations. We measured
the effect of therapy by monitoring BMD change.
Although this is a surrogate endpoint, the primary goal of
treatment remains fracture reduction. However, to meas-
ure fracture reduction, large numbers of patients are
required, particularly in a trial with a non inferiority
design.[11] Nevertheless, there are some data that suggest
that larger increases in BMD are correlated with lower frac-
ture rates. [12-14]
Additionally, the study population may be subject to
selection bias, since the patients treated with pamidronate
had gastrointestinal problems. Although we can not
exclude that the two groups were slightly different, there
were no differences in risk factors for osteoporosis
between the groups. Moreover, the pre-treatment period
with oral bisphosphonates was short, thus their effect on
bone mineral density during this period will be minimal.
Because of the fact that it is a retrospective study and only
patients who tolerated treatment for at least two years
were included, it was not possible to perform a risk benefit
calculation. Nevertheless, our data clearly show that for
these patients, who tolerate their treatment regimes, the
response in BMD is comparable.
Recently, new data of large randomized controlled trials
have become available, which showed that treatment with
either zoledronate or ibandronate iv compared to placebo
(three years and one year respectively) has a superior
effect on BMD in postmenopausal women, and leads to
fracture reduction. [15,16] However, in our study, we
present data over a longer observation time (four years).
Moreover, and more important, we compared the changes
of BMD during an intravenous regime with that of widely
prescribed oral bisphosphonates, usually regarded as first
choice of treatment, instead of a comparison with placebo
treatment, which was the case in the zoledronate and
ibandronate studies.
In conclusion, our present study demonstrates that treat-
ment during four years with intravenous pamidronate has
a comparable effect on change in BMD as treatment with
either alendronate or risedronate. We therefore suggest to
consider treatment with intravenous pamidronate as an
alternative treatment for patients diagnosed with oste-
oporosis who have gastrointestinal side effects during
treatment with oral bisphosphonates or contraindications
for oral bisphosphonates.
Conclusion
The results of the present study demonstrate, that long
term treatment with pamidronate iv has a comparable
effect on BMD as oral bisphosphonates. In both groups
the BMD of the spine increased with more than six per-
cent, while the BMD of the hip remained stable.
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